

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
07 July 2022 (07.07.2022)



(10) International Publication Number  
**WO 2022/147222 A1**

(51) International Patent Classification:

A61P 35/04 (2006.01) A61K 39/395 (2006.01)  
C07K 16/28 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/065649

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

30 December 2021 (30.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/132,584 31 December 2020 (31.12.2020) US  
63/166,042 25 March 2021 (25.03.2021) US

(71) Applicant: **NOVAROCK BIOTHERAPEUTICS, LTD.**  
[US/US]; 801 Charles Ewing Blvd., Ewing, NJ 08628 (US).

(72) Inventors: **PEI, Yi**; 1836 Glenwold Drive, Pennsylvania 19301, Paoli, PA 19301 (US). **HUANG, Haichun**; 2425 Sueno Way, Fremont, CA 94539 (US). **LEI, Ming**; 20 Lockwood Drive, Princeton, NJ 08540 (US). **LI, Han**; 1 Claire Dr., Newtown, PA 18940 (US). **SUM, Chi, Shing**; 417 Mahogany Walk, Newtown, PA 18940 (US). **PRITSKER, Alla**; 142 Bramble Drive, Morganville, NJ 07751 (US). **LIN, Bor-Ruei**; 31 Haggerty Drive, West Orange, NJ 07052 (US). **TANG, Fangqiang**; 465 Meadow Road, APT 6205, Princeton, NJ 08540 (US).

(74) Agent: **BETTI, Christopher, J.**; Morgan, Lewis & Bockius LLP, 110 North Wacker Drive, Suite 2800, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODIES TO TNFR2 AND USES THEREOF

(57) Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to human TNFR2. The disclosed antibodies, inhibit the TNF-TNFR2 signaling axis and enhance cytokine secretion in T effector cells and are therefore useful for the treatment of cancer, either alone or in combination with other agents.

WO 2022/147222 A1